Compare LASR & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASR | LGND |
|---|---|---|
| Founded | 2000 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.7B |
| IPO Year | 2018 | N/A |
| Metric | LASR | LGND |
|---|---|---|
| Price | $75.36 | $305.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $54.31 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 1.4M | 489.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.99 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $191,359,000.00 | N/A |
| Revenue This Year | $10.91 | $1.25 |
| Revenue Next Year | $14.32 | $19.41 |
| P/E Ratio | $6,831.00 | ★ $76.27 |
| Revenue Growth | ★ 38.09 | N/A |
| 52 Week Low | $18.62 | $131.67 |
| 52 Week High | $86.95 | $326.63 |
| Indicator | LASR | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 57.83 | 57.80 |
| Support Level | $55.45 | $180.85 |
| Resistance Level | $83.49 | $326.63 |
| Average True Range (ATR) | 6.37 | 11.38 |
| MACD | 0.92 | -4.31 |
| Stochastic Oscillator | 93.76 | 37.50 |
nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.